Page last updated: 2024-12-11
bo 653
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
2,3-dihydro-5-hydroxy-2,2-dipentyl-4,6-di-tert-butylbenzofuran: an antiatherogenic antioxidant; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 9800472 |
CHEMBL ID | 104186 |
SCHEMBL ID | 5055886 |
MeSH ID | M0277494 |
Synonyms (17)
Synonym |
---|
CHEMBL104186 |
bo-653 |
157360-23-1 |
2,3-dihydro-5-hydroxy-2,2-dipentyl-4,6-di-tert-butylbenzofuran |
2vsp9t5lrx , |
unii-2vsp9t5lrx |
bo 653 |
2,3-dihydro-5-hydroxy-4,6-di-tert-butyl-2,2-dipentylbenzofuran |
4,6-ditert-butyl-2,2-dipentyl-3h-benzofuran-5-ol |
4,6-di-t-butyl-5-hydroxy-2,2-di-n-pentyl-2,3-dihydrobenzofuran |
AGURKSYKTJQPNA-UHFFFAOYSA-N |
4,6-di-tert-butyl-5-hydroxy-2,2-dipentyl-2,3-dihydrobenzofuran |
SCHEMBL5055886 |
DTXSID20166253 |
4,6-bis(1,1-dimethylethyl)-2,3-dihydro-2,2-dipentyl-5-benzofuranol |
5-benzofuranol, 4,6-bis(1,1-dimethylethyl)-2,3-dihydro-2,2-dipentyl- |
4,6-ditert-butyl-2,2-dipentyl-3h-1-benzofuran-5-ol |
Research Excerpts
Bioavailability
Excerpt | Reference | Relevance |
---|---|---|
"We examined the design of the versatile novel self-emulsifying drug delivery systems (SEDDS) type O/W microemulsion formulation which enhances the oral bioavailability by raising the solubility of poorly water soluble compounds." | ( The novel formulation design of self-emulsifying drug delivery systems (SEDDS) type O/W microemulsion I: enhancing effects on oral bioavailability of poorly water soluble compounds in rats and beagle dogs. Araya, H; Hayashi, M; Nagao, S; Tomita, M, 2005) | 0.33 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (12)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID29847 | Distribution of compound into HDL lipoprotein fraction of WHHL Rabbit's plasma after oral administration | 2003 | Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14 | Design and synthesis of 4,6-di-tert-butyl-2,3-dihydro-5-benzofuranols as a novel series of antiatherogenic antioxidants. |
AID29926 | Distribution of compound into VLDL lipoprotein fraction of WHHL Rabbit's plasma after oral administration | 2003 | Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14 | Design and synthesis of 4,6-di-tert-butyl-2,3-dihydro-5-benzofuranols as a novel series of antiatherogenic antioxidants. |
AID26958 | cLogP was determined | 2003 | Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14 | Design and synthesis of 4,6-di-tert-butyl-2,3-dihydro-5-benzofuranols as a novel series of antiatherogenic antioxidants. |
AID28408 | Distribution of compound into WHHL Rabbit's plasma after oral administration | 2003 | Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14 | Design and synthesis of 4,6-di-tert-butyl-2,3-dihydro-5-benzofuranols as a novel series of antiatherogenic antioxidants. |
AID100078 | Inhibition of LDL oxidation induced by cupric ions (CuSO4) at 1 uM expressed as % control. | 2003 | Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14 | Design and synthesis of 4,6-di-tert-butyl-2,3-dihydro-5-benzofuranols as a novel series of antiatherogenic antioxidants. |
AID100079 | Inhibition of LDL oxidation induced by cupric ions (CuSO4) at 10 uM expressed as % control. | 2003 | Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14 | Design and synthesis of 4,6-di-tert-butyl-2,3-dihydro-5-benzofuranols as a novel series of antiatherogenic antioxidants. |
AID100080 | Inhibition of LDL oxidation induced by soybean lipoxygenase (SLO) at 0.5 uM expressed as % control. | 2003 | Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14 | Design and synthesis of 4,6-di-tert-butyl-2,3-dihydro-5-benzofuranols as a novel series of antiatherogenic antioxidants. |
AID27547 | Distribution of compound into LDL lipoprotein fraction of WHHL Rabbit's plasma after oral administration | 2003 | Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14 | Design and synthesis of 4,6-di-tert-butyl-2,3-dihydro-5-benzofuranols as a novel series of antiatherogenic antioxidants. |
AID100081 | Inhibition of LDL oxidation induced by soybean lipoxygenase (SLO) at 5 uM expressed as % control. | 2003 | Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14 | Design and synthesis of 4,6-di-tert-butyl-2,3-dihydro-5-benzofuranols as a novel series of antiatherogenic antioxidants. |
AID326215 | Antioxidant activity assessed as oxygen radical scavenging activity in presence of human plasma by ORAC method relative to control | 2008 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 18, Issue:7 | Antioxidant capacity of BO-653, 2,3-dihydro-5-hydroxy-4,6-di-tert-butyl-2,2-dipentylbenzofuran, and uric acid as evaluated by ORAC method and inhibition of lipid peroxidation. |
AID226841 | Inhibition of MCLA chemiluminescence generated by autoxidation of linoleic acid | 2003 | Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14 | Design and synthesis of 4,6-di-tert-butyl-2,3-dihydro-5-benzofuranols as a novel series of antiatherogenic antioxidants. |
AID326216 | Antioxidant activity in human plasma assessed as inhibition of cholesteryl ester hydroperoxide formation after 60 mins relative to control | 2008 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 18, Issue:7 | Antioxidant capacity of BO-653, 2,3-dihydro-5-hydroxy-4,6-di-tert-butyl-2,2-dipentylbenzofuran, and uric acid as evaluated by ORAC method and inhibition of lipid peroxidation. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (23)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 5 (21.74) | 18.2507 |
2000's | 16 (69.57) | 29.6817 |
2010's | 2 (8.70) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 16.39
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (16.39) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 1 (4.17%) | 5.53% |
Reviews | 4 (16.67%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 19 (79.17%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |